{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:05:26Z","timestamp":1794567926133,"version":"4.9.1"},"reference-count":172,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jaccao.2024.07.017","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T14:46:23Z","timestamp":1727189183000},"page":"631-654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":92,"title":["Cardiovascular Considerations Before Cancer Therapy"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7757-5465","authenticated-orcid":false,"given":"Zahra","family":"Raisi-Estabragh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4248-7537","authenticated-orcid":false,"given":"Alexandra C.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivatharshini","family":"Ramalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle","family":"Scherrer-Crosbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3414-7022","authenticated-orcid":false,"given":"Teresa","family":"Lopez-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Aznar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Cordoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bredsen-Masley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashu","family":"Wechalekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5994-5998","authenticated-orcid":false,"given":"Richard K.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0245-7090","authenticated-orcid":false,"given":"Charlotte H.","family":"Manisty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2024.07.017_bib1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2024.07.017_bib2","first-page":"1","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"3","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2024.07.017_bib3","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/heartjnl-2022-321888","article-title":"Incident cardiovascular events and imaging phenotypes in UK Biobank participants with past cancer","volume":"109","author":"Raisi-Estabragh","year":"2023","journal-title":"Heart"},{"key":"10.1016\/j.jaccao.2024.07.017_bib4","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2024.07.017_bib5","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cjca.2016.02.078","article-title":"Canadian Cardiovascular Society Guidelines for evaluation and management of cardiovascular complications of cancer therapy","volume":"32","author":"Virani","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib6","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American society of echocardiography and the European association of cardiovascular imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.jaccao.2024.07.017_bib7","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1002\/cncr.31695","article-title":"Congestive heart failure in older adults diagnosed with follicular lymphoma: a population-based study","volume":"124","author":"Kenzik","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jaccao.2024.07.017_bib8","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1158\/1078-0432.CCR-20-4162","article-title":"Association of cardiovascular disease risk factors with late cardiotoxicity and survival in HER2-positive breast cancer survivors","volume":"27","author":"He","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaccao.2024.07.017_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaccao.2020.12.005","article-title":"The Incidence, risk factors, and outcomes with 5-fluorouracil-associated coronary vasospasm","volume":"3","author":"Zafar","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib10","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1200\/JCO.2013.51.1055","article-title":"Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study","volume":"32","author":"Armstrong","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib11","article-title":"Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review","volume":"6","author":"Porta-S\u00e1nchez","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2024.07.017_bib12","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart\u00a0Failure Association of the European Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jaccao.2024.07.017_bib13","article-title":"Efficacy of physical exercise to offset anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of clinical and preclinical studies","volume":"10","author":"Naaktgeboren","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2024.07.017_bib14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/eurjpc\/zwab006","article-title":"The role of exercise in the prevention of cancer therapy-related cardiac dysfunction in breast cancer patients undergoing chemotherapy: systematic review","volume":"29","author":"Murray","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib15","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCULATIONAHA.122.062814","article-title":"Exercise for the prevention of anthracycline-induced functional disability and cardiac dysfunction: the BREXIT study","volume":"147","author":"Foulkes","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2024.07.017_bib16","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/CIRCULATIONAHA.122.062946","article-title":"Randomized controlled trial of a smartphone-based intervention to enhance 6-minute walk distance during breast cancer treatment: the SMART-BREAST trial","volume":"147","author":"Murphy","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2024.07.017_bib17","doi-asserted-by":"crossref","first-page":"907","DOI":"10.7326\/0003-4819-138-11-200306030-00012","article-title":"The epidemiology of \u201casymptomatic\u201d left ventricular systolic dysfunction: implications for screening","volume":"138","author":"Wang","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaccao.2024.07.017_bib18","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jacc.2022.08.743","article-title":"Advances in multimodality imaging in cardio-oncology: JACC state-of-the-art review","volume":"80","author":"Baldassarre","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib19","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2024.07.017_bib20","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s10554-019-01648-z","article-title":"Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study","volume":"35","author":"Dhir","year":"2019","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2024.07.017_bib21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/heartjnl-2019-316297","article-title":"Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity","volume":"106","author":"Lambert","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.jaccao.2024.07.017_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12968-022-00844-6","article-title":"30-minute CMR for common clinical indications: a Society for Cardiovascular Magnetic Resonance white paper","volume":"24","author":"Raman","year":"2022","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"key":"10.1016\/j.jaccao.2024.07.017_bib23","doi-asserted-by":"crossref","first-page":"661","DOI":"10.7326\/M13-2266","article-title":"Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects","volume":"160","author":"Yeh","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaccao.2024.07.017_bib24","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/10428194.2022.2140289","article-title":"External validation of a heart failure risk score in patients with acute myeloid leukemia","volume":"64","author":"Doukas","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaccao.2024.07.017_bib25","first-page":"977","article-title":"Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines","volume":"16","author":"Mousavi","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2024.07.017_bib26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaccao.2019.10.008","article-title":"Symptomatic heart failure in acute leukemia patients treated with anthracyclines","volume":"1","author":"Kang","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib27","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCIMAGING.114.002217","volume":"7","author":"Jordan","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2024.07.017_bib28","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamacardio.2023.0494","article-title":"Comprehensive cardiovascular magnetic resonance tissue characterization and cardiotoxicity in women with breast cancer","volume":"8","author":"Thavendiranathan","year":"2023","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib29","article-title":"Does cardiac imaging surveillance strategy influence outcomes in patients with early breast cancer?","volume":"13","author":"Wu","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10549-019-05178-z","article-title":"Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy","volume":"176","author":"Abu-Khalaf","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaccao.2024.07.017_bib31","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jcct.2019.03.007","article-title":"Coronary atherosclerosis imaging by CT to improve clinical outcomes","volume":"13","author":"Williams","year":"2019","journal-title":"J\u00a0Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.jaccao.2024.07.017_bib32","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcct.2022.09.002","article-title":"Cardiac computed tomographic imaging in cardio-oncology: an expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS)","volume":"17","author":"Lopez-Mattei","year":"2023","journal-title":"J\u00a0Cardiovasc Comput Tomogr"},{"key":"10.1016\/j.jaccao.2024.07.017_bib33","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","article-title":"Early detection and prediction of cardiotoxicity in chemotherapy-treated patients","volume":"107","author":"Sawaya","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib34","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s12282-017-0778-8","article-title":"High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients","volume":"24","author":"Kitayama","year":"2017","journal-title":"Breast Cancer"},{"key":"10.1016\/j.jaccao.2024.07.017_bib35","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2193-1801-3-620","article-title":"High-sensitivity troponin T as a marker to predict cardiotoxicity in breast cancer patients with adjuvant trastuzumab therapy","volume":"3","author":"Katsurada","year":"2014","journal-title":"Springerplus"},{"key":"10.1016\/j.jaccao.2024.07.017_bib37","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10549-017-4628-3","article-title":"Cardiac biomarkers for early detection and prediction of trastuzumab and\/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)","volume":"168","author":"Ponde","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jaccao.2024.07.017_bib38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijcard.2009.09.564","article-title":"Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide","volume":"148","author":"Feola","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib39","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","volume":"35","author":"Zardavas","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib40","first-page":"23","article-title":"Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy \u2013 a prospective analysis","volume":"9","author":"Dean","year":"2023","journal-title":"Cardiooncology"},{"key":"10.1016\/j.jaccao.2024.07.017_bib41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3109\/1354750X.2015.1040839","article-title":"New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide","volume":"20","author":"Van Boxtel","year":"2015","journal-title":"Biomarkers"},{"key":"10.1016\/j.jaccao.2024.07.017_bib42","first-page":"2569","article-title":"Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab","volume":"33","author":"Lemieux","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jaccao.2024.07.017_bib43","first-page":"286","article-title":"Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin\/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy","volume":"13","author":"Tan","year":"2020","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib44","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/annonc\/mdm181","article-title":"Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity","volume":"18","author":"Beauclair","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib45","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/bjh.12516","article-title":"Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation","volume":"163","author":"Armenian","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib46","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaccao.2021.11.008","article-title":"Cardiovascular disease among patients with AML and CHIP-related mutations","volume":"4","author":"Calvillo-Arg\u00fcelles","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib47","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/ehf2.13897","article-title":"The new HFA\/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity","volume":"9","author":"Di Lisi","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jaccao.2024.07.017_bib48","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ijcard.2021.11.059","article-title":"Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: the HFA\/ICOS risk tool in real-world practice","volume":"349","author":"Tini","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib49","article-title":"HFA-ICOS cardiovascular toxicity risk score validation in CARDIOTOX registry (abstr)","volume":"43","author":"Rivero","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaccao.2024.07.017_bib50","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaccao.2023.04.004","article-title":"Cardiotoxicity of BRAF\/MEK inhibitors: a longitudinal study incorporating contemporary definitions and risk scores","volume":"5","author":"Glen","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib51","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0569","article-title":"Risk prediction models for cardiotoxicity of chemotherapy among patients with breast cancer: a systematic review","volume":"6","author":"Kabor\u00e9","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaccao.2024.07.017_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-020-01659-x","article-title":"Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care","volume":"18","author":"Bidulka","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.jaccao.2024.07.017_bib53","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1161\/HYPERTENSIONAHA.120.16454","article-title":"Mechanisms underlying vascular endothelial growth factor receptor inhibition-induced hypertension: the HYPAZ trial","volume":"77","author":"M\u00e4ki-Pet\u00e4j\u00e4","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.jaccao.2024.07.017_bib54","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","article-title":"Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases","volume":"49","author":"Walker","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaccao.2024.07.017_bib55","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib56","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/cncr.33470","article-title":"Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study","volume":"127","author":"Pastori","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jaccao.2024.07.017_bib57","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.3390\/cancers15092574","article-title":"Systematic review and meta-analysis of oral anticoagulant therapy in atrial fibrillation cancer patients","volume":"15","author":"Cereda","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.jaccao.2024.07.017_bib58","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ehjqcco\/qcy040","article-title":"Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF","volume":"5","author":"Chen","year":"2019","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.jaccao.2024.07.017_bib59","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","article-title":"Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial","volume":"130","author":"Melloni","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.jaccao.2024.07.017_bib60","article-title":"Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - TIMI 48 trial","volume":"7","author":"Fanola","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2024.07.017_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/heartjnl-2022-320810","article-title":"Joint British Society consensus recommendations for magnetic resonance imaging for patients with cardiac implantable electronic devices guideline or consensus statement","volume":"110","author":"Bhuva","year":"2024","journal-title":"Heart"},{"key":"10.1016\/j.jaccao.2024.07.017_bib62","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.hrthm.2017.04.025","article-title":"2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices","volume":"14","author":"Indik","year":"2017","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jaccao.2024.07.017_bib63","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcin.2018.10.026","article-title":"Transcatheter aortic valve replacement in oncology patients with severe aortic stenosis","volume":"12","author":"Landes","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jaccao.2024.07.017_bib64","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/ehf2.13782","article-title":"Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters","volume":"9","author":"D\u00edaz-Ant\u00f3n","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jaccao.2024.07.017_bib65","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.amjcard.2015.04.064","article-title":"Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy","volume":"116","author":"Wang","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib66","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.8685","article-title":"Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: results from a randomized prospective clinical trial","volume":"7","author":"Xue","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaccao.2024.07.017_bib67","article-title":"Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction","volume":"9","author":"Demissei","year":"2020","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2024.07.017_bib68","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/CIRCULATIONAHA.123.064274","article-title":"Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta-blocker therapy to prevent anthracycline cardiotoxicity: the Cardiac CARE trial","volume":"148","author":"Henriksen","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2024.07.017_bib69","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaccao.2023.10.008","article-title":"Impact of the ESC cardio-oncology guidelines biomarker criteria on incidence of cancer therapy-related cardiac dysfunction","volume":"6","author":"Mecinaj","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib70","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic variants associated with cancer therapy\u2013induced cardiomyopathy","volume":"140","author":"Garcia-Pavia","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2024.07.017_bib71","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","article-title":"NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity","volume":"112","author":"Wojnowski","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2024.07.017_bib72","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children\u2019s Oncology Group","volume":"30","author":"Blanco","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib73","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jaccao.2023.05.004","article-title":"Cardioprotection in patients at high risk of anthracycline-induced cardiotoxicity: JACC: CardioOncology primer","volume":"5","author":"Henriksen","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib74","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.ejca.2015.07.031","article-title":"Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis","volume":"51","author":"Yamaguchi","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jaccao.2024.07.017_bib75","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","article-title":"Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer","volume":"1","author":"Macedo","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib76","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1200\/JCO.1997.15.4.1333","article-title":"Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy","volume":"15","author":"Swain","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib77","article-title":"Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines","volume":"9","author":"de Baat","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaccao.2024.07.017_bib78","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/annonc\/mdj134","article-title":"Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced\/metastatic breast cancer patients treated with anthracycline-based chemotherapy","volume":"17","author":"Marty","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib81","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11739-020-02508-8","article-title":"Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis","volume":"16","author":"Caspani","year":"2021","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jaccao.2024.07.017_bib82","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","article-title":"Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib83","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","article-title":"Sodium-glucose co-transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines","volume":"10","author":"Gongora","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jaccao.2024.07.017_bib84","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jaccao.2024.07.017_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101885","article-title":"Statins for attenuating cardiotoxicity in patients receiving anthracyclines: a systematic review and meta-analysis","volume":"48","author":"Titus","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib86","article-title":"Statins and left ventricular ejection fraction following doxorubicin treatment","volume":"9","author":"Hundley","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jaccao.2024.07.017_bib87","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","article-title":"Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines","volume":"9","author":"Thavendiranathan","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jaccao.2024.07.017_bib88","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3322\/caac.21583","article-title":"Breast cancer statistics","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jaccao.2024.07.017_bib89","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2024.07.017_bib90","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib91","first-page":"CD006243","article-title":"Trastuzumab containing regimens for early breast cancer","volume":"2012","author":"Moja","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaccao.2024.07.017_bib92","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"Romond","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib93","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib94","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib95","series-title":"Herceptin final labeling","year":"2010"},{"key":"10.1016\/j.jaccao.2024.07.017_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100723","article-title":"Conventional cardiac risk factors associated with trastuzumab-induced cardiotoxicity in breast cancer: systematic review and meta-analysis","volume":"45","author":"Koulaouzidis","year":"2021","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.jaccao.2024.07.017_bib97","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2024.07.017_bib98","article-title":"Trastuzumab in female breast cancer patients with reduced left ventricular ejection fraction","volume":"7","author":"Nowsheen","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2024.07.017_bib99","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14740338.2017.1351541","article-title":"Breast cancer treatment-induced cardiotoxicity","volume":"16","author":"Martel","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jaccao.2024.07.017_bib100","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1200\/JCO.2009.26.0463","article-title":"Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial","volume":"28","author":"Procter","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib101","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","article-title":"Permissive cardiotoxicity: the clinical crucible of cardio-oncology","volume":"4","author":"Porter","year":"2022","journal-title":"Cardiooncology"},{"key":"10.1016\/j.jaccao.2024.07.017_bib102","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1103941","article-title":"Chemotherapy induced right ventricular cardiomyopathy; a systematic review and meta-analysis","volume":"10","author":"Theetha Kariyanna","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jaccao.2024.07.017_bib103","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1200\/JCO.2010.32.7353","article-title":"Troponin I as a predictor for trastuzumab-related cardiotoxicity: current data do not provide mechanistic insights or allow for incorporation into clinical practice","volume":"29","author":"Goel","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib104","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaccao.2022.10.010","article-title":"The ESC cardio-oncology guidelines: a roadmap for clinical practice and generating needed evidence","volume":"5","author":"Sparano","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib105","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jaccao.2022.10.008","article-title":"ESC cardio-oncology guidelines: a triumph\u2014but are we overscreening?","volume":"5","author":"Witteles","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib106","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.jaccao.2024.07.017_bib107","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib108","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12885-015-1298-6","article-title":"Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity","volume":"15","author":"Stanton","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jaccao.2024.07.017_bib109","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1248\/bpb.b19-00527","article-title":"A\u00a0genome-wide association study identifies five novel genetic markers for trastuzumab-induced cardiotoxicity in Japanese population","volume":"42","author":"Nakano","year":"2019","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jaccao.2024.07.017_bib110","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fcvm.2020.00142","article-title":"Association of genetic variants at TRPC6 with chemotherapy-related heart failure","volume":"7","author":"Norton","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jaccao.2024.07.017_bib111","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib112","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib113","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib114","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11912-021-01114-x","article-title":"Cardiovascular toxicity of novel HER2-targeted therapies in the treatment of breast cancer","volume":"23","author":"Dent","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jaccao.2024.07.017_bib115","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jaccao.2022.09.007","article-title":"Pharmacovigilance analysis of heart failure associated with anti-HER2 monotherapies and combination regimens for cancer","volume":"5","author":"Waliany","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib116","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijcard.2019.01.038","article-title":"Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease","volume":"280","author":"Totzeck","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib117","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.clcc.2018.10.006","article-title":"5-fluorouracil-related cardiotoxicity; findings from five randomized studies of 5-fluorouracil-based regimens in metastatic colorectal cancer","volume":"18","author":"Abdel-Rahman","year":"2019","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"10.1016\/j.jaccao.2024.07.017_bib118","first-page":"22","article-title":"Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study","volume":"38","author":"Peng","year":"2018","journal-title":"Cancer Commun (Lond)"},{"issue":"2","key":"10.1016\/j.jaccao.2024.07.017_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100788","article-title":"Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy","volume":"8","author":"Gouda","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.jaccao.2024.07.017_bib120","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaccao.2024.07.017_bib121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","article-title":"Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Glen","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib122","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2024.07.017_bib123","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.42676","article-title":"Statin use and survival among men receiving androgen-ablative therapies for advanced prostate cancer: a systematic review and meta-analysis","volume":"5","author":"Jayalath","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaccao.2024.07.017_bib124","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/bju.15851","article-title":"Phase II proof-of-concept study of atorvastatin in castration-resistant prostate cancer","volume":"131","author":"Rushworth","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.jaccao.2024.07.017_bib125","article-title":"Statin use is associated with better prognosis of patients with prostate cancer after definite therapies: a systematic review and meta-analysis of cohort studies","volume":"2022","author":"An","year":"2022","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib126","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2014.60.2557","article-title":"Prostate cancer survivorship care guideline: American Society of Clinical Oncology clinical practice guideline endorsement","volume":"33","author":"Resnick","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib127","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eururo.2020.06.002","article-title":"Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: a meta-analysis of randomized controlled trials","volume":"79","author":"Abufaraj","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib128","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1136\/heartjnl-2020-318748","article-title":"Optimising cardiovascular care of patients with multiple myeloma","volume":"107","author":"Fontes Oliveira","year":"2021","journal-title":"Heart"},{"issue":"13","key":"10.1016\/j.jaccao.2024.07.017_bib129","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.3390\/cancers14133049","article-title":"Mortality and major cardiovascular events among patients with multiple myeloma: analysis from a nationwide French Medical Information Database","volume":"14","author":"Cottin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jaccao.2024.07.017_bib130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Georgiopoulos","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib131","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib132","first-page":"1183","article-title":"The value of troponin as a biomarker of chemotherapy-induced cardiotoxicity","volume":"12","author":"Sorodoc","year":"2022","journal-title":"Life (Basel)"},{"key":"10.1016\/j.jaccao.2024.07.017_bib133","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-associated atrial fibrillation","volume":"4","author":"Ganatra","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib134","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood.2022018818","article-title":"Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial","volume":"142","author":"Seymour","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2024.07.017_bib135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2010.08.020","article-title":"A\u00a0prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib","volume":"35","author":"Raisi-Estabragh","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaccao.2024.07.017_bib136","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-134912","article-title":"Long-term cardiac, vascular, and hypertension safety of bosutinib (BOS) versus imatinib (IMA) for newly diagnosed chronic myeloid leukemia (CML): results from the Bfore trial","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2024.07.017_bib137","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2024.07.017_bib138","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2024.07.017_bib139","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00217-2017","article-title":"Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study","volume":"50","author":"Weatherald","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaccao.2024.07.017_bib141","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jaccao.2024.07.017_bib142","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jaccao.2024.07.017_bib143","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2024.07.017_bib144","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2024.07.017_bib145","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib146","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib147","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2024.07.017_bib148","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaccao.2021.01.004","article-title":"Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors","volume":"3","author":"Waliany","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib149","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13400","article-title":"Pre-treatment high-sensitivity troponin T for the short-term prediction of cardiac outcomes in patients on immune checkpoint inhibitors","volume":"51","author":"Petricciuolo","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jaccao.2024.07.017_bib150","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jaccao.2022.11.008","article-title":"Pre-existing autoimmune disease increases the risk of cardiovascular and noncardiovascular events after immunotherapy","volume":"4","author":"Lee","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib151","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2024.07.017_bib152","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib153","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijcard.2020.08.024","article-title":"Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy","volume":"322","author":"Schiffer","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib154","article-title":"Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem","volume":"9","author":"Poels","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jaccao.2024.07.017_bib155","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2024.07.017_bib156","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib157","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11912-021-01068-0","article-title":"Cardiovascular toxicities of CAR T-cell therapy","volume":"23","author":"Patel","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jaccao.2024.07.017_bib158","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib159","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T CELL THERAPY: A RETROSPECTIVE STUDY","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib160","article-title":"Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies","volume":"8","author":"Shalabi","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jaccao.2024.07.017_bib161","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib162","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamaoncol.2020.7468","article-title":"Association of breast cancer irradiation with cardiac toxic effects: a narrative review","volume":"7","author":"Meattini","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib163","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"Van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jaccao.2024.07.017_bib164","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2024.07.017_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.109453","article-title":"Radiation dose to heart and cardiac substructures and risk of coronary artery disease in early breast cancer patients: a DBCG study based on modern radiation therapy techniques","volume":"180","author":"Holm Milo","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib166","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41409-020-01080-1","article-title":"Cardiovascular risk assessment and management of patients undergoing hematopoietic cell transplantation","volume":"56","author":"Oliveira","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaccao.2024.07.017_bib167","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jaccao.2021.01.008","article-title":"Role of physical activity and cardiac rehabilitation in patients undergoing hematopoietic stem cell transplantation","volume":"3","author":"Mohananey","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib168","article-title":"Inequity in cardio-oncology: identifying disparities in cardiotoxicity and links to cardiac and cancer outcomes","volume":"10","author":"Ohman","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2024.07.017_bib169","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jaccao.2021.05.001","article-title":"Racial and ethnic disparities in cardio-oncology: a call to action","volume":"3","author":"Fazal","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib170","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12170-020-00650-8","article-title":"Cardio-oncology preventive care: racial and ethnic disparities","volume":"14","author":"Prasad","year":"2020","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"10.1016\/j.jaccao.2024.07.017_bib171","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.31260","article-title":"Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer","volume":"124","author":"Litvak","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jaccao.2024.07.017_bib172","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jaccao.2022.06.005","article-title":"Impact of social vulnerability on comorbid cancer and cardiovascular disease mortality in the United States","volume":"4","author":"Ganatra","year":"2022","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.jaccao.2024.07.017_bib173","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa035153","article-title":"The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia","volume":"351","author":"Lipshultz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2024.07.017_bib174","doi-asserted-by":"crossref","first-page":"9698","DOI":"10.1038\/s41598-017-09517-2","article-title":"Hypertension susceptibility loci are associated with anthracycline-related cardiotoxicity in long-term childhood cancer survivors","volume":"7","author":"Hildebrandt","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaccao.2024.07.017_bib175","article-title":"Baseline blood pressure and development of cardiotoxicity in patients treated with anthracyclines: a systematic review","volume":"15","author":"Philip","year":"2022","journal-title":"Int J Cardiol Cardiovasc Risk Prev"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087324002771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087324002771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T12:21:51Z","timestamp":1733314911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087324002771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":172,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2666087324002771"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.017","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Considerations Before Cancer Therapy","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}